Humanized models are an amazing tool in the search for new cancer therapies, but they aren’t good enough. Yet. There are two major obstacles standing in the way of these tools becoming a standard used to test immunotherapies: incorporation of the human immune system and cost.

This webinar addresses how Charles River is making strides in both of these areas with our new mouse model (the NCG triple immunodeficient mouse) and approaches to maximizing the output of the engrafted immune cells.


  • Paula Miliani de Marval, PhD, Research Scientist, Charles River